Biopharmaceutical segment occupies around 75 per cent in the pi-chart of the Indian Biotechnology sector, which is on a fast-growth track – targeting to reach $10-billion revenue by 2015 from $4 billion posted in the last fiscal. Bangalore-based Sartorius Stedim India is all set to boost this growth. In an exclusive interview with PROCESS India, Amit Chatterjee, Managing Director of the company, reveals his company’s strength and service strategy for the Indian market.
Read on